NCT03205995View on ClinicalTrials.gov

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 23, 2017

Primary Completion Date

February 29, 2020

Study Completion Date

February 29, 2020

Conditions
Thrombotic MicroangiopathiesAtypical Hemolytic Uremic Syndrome
Interventions
BIOLOGICAL

OMS721

Intravenous loading dose followed by daily subcutaneous injections

Trial Locations (2)

60643

RECRUITING

Omeros Investigational Site, Chicago

90025

NOT_YET_RECRUITING

Omeros Investigational Site, Los Angeles

Sponsors

Lead Sponsor

Omeros Corporation
All Listed Sponsors
lead

Omeros Corporation

INDUSTRY

NCT03205995 - Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome | Biotech Hunter | Biotech Hunter